Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
- Author(s)
- 정경해; Andreas Koehler; Anh Nguyen Duc; Carlos H Barrios; Cristiano Ferrario; Elizabeth A Mittendorf; Frederique Penault-Llorca; Hiroji Iwata; Hong Zhang; Joohyuk Sohn; Kevin Punie; Luciana Molinero; Mario Liste-Hermoso; Melinda L Telli; Nadia Harbeck; Roberto Hegg; Shigehira Saji; Shilpen Patel; Stephen Y Chui; Vidy
- Issued Date
- 2020
- Type
- Article
- Keyword
- Science & Technology; Life Sciences & Biomedicine; Medicine; General & Internal; General & Internal Medicine; CARBOPLATIN; WOMEN; Adult; Albumins; Antibodies; Monoclonal; Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Double-Blind Method, Doxorubicin, Female, Humans, Middle Aged, Neoadjuvant Therapy, Paclitaxel, Triple Negative Breast Neoplasms, 11 Medical and Health Sciences, 32 Biomedical and clinical sciences, 42 Health sciences
- DOI
- 10.1016/S0140-6736(20)31953-X
- URI
- https://oak.ulsan.ac.kr/handle/2021.oak/11821
- Publisher
- LANCET
- Language
- 영어
- ISSN
- 0140-6736
- Citation Volume
- 396
- Citation Number
- 10257
- Citation Start Page
- 1090
- Citation End Page
- 1100
-
Appears in Collections:
- Medicine > Medicine
- Authorize & License
-
- Files in This Item:
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.